TOP > 外国特許検索 > AMIDE COMPOUND AND DRUG COMPRISING SAME

AMIDE COMPOUND AND DRUG COMPRISING SAME

外国特許コード F150008358
整理番号 E112P04P1WO
掲載日 2015年6月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP082521
国際公開番号 WO 2015087865
国際出願日 平成26年12月9日(2014.12.9)
国際公開日 平成27年6月18日(2015.6.18)
優先権データ
  • 特願2013-254908 (2013.12.10) JP
  • 特願2014-112179 (2014.5.30) JP
発明の名称 (英語) AMIDE COMPOUND AND DRUG COMPRISING SAME
発明の概要(英語) Provided is a novel compound which has excellent Aβ aggregation inhibition effects and is useful as a drug. The present invention is an amide compound represented by general formula (1) or a salt thereof. (In the formula, Z is CH or N, A and B are the same or different and is -CH2-, -O-, -S-, or -NH-, R1 and R2 are the same or different and is a branched chain alkyl group, a branched chain alkenyl group, an aromatic hydrocarbon group which may have a substituent, an aralkyl group which may have a substituent, a cycloalkyl group which may have a substituent, or an aromatic heterocyclic group which may have a substituent, and R3 is a branched chain alkyl group, a branched chain alkenyl group, a cycloalkyl group which may have a substituent, or an aralkyl group which may have a substituent.) (1)
従来技術、競合技術の概要(英語) BACKGROUND ART
Alzheimer's disease is degeneration of nerve cells, senile plaques and falling off the formation of the pathological features of neurofibrillary tangles has disease is a neurodegenerative disease. Alzheimer's disease is memory, recognition, thinking, it is determined that there is a progressive loss of cognitive symptoms such as cause, eventually leading to death. Deposited in the brain senile plaques is the amyloid β peptide constituting the main protein (A β) and, consisting of 39-43 amino acids. A β cell toxicity, which are thought to be caused by Alzheimer's disease (non-patent document 1) are. A β 40 is mainly secreted from the one or 42 amino acids and polypeptides, in particular 42 consists of one A β in the brain have a strong property of the aggregation is deposited on the early, has a strong cytotoxicity (non-patent document 2) are known. Therefore, agents that inhibits aggregation of A β, Alzheimer's disease prevention has been expected as a therapeutic agent.
A β is a subsequence of a L-[Lys-Leu-Val-Phe-Phe], has an activity to A β inhibition (non-patent document 3) are known.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • KANAI, Motomu
  • SOMA, Yohei
  • ARAI, Tadamasa
  • ARAYA, Takushi
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) ERATO KANAI Life Science Catalysis AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close